Cite
HARVARD Citation
Richard Hobbs, F. et al. (n.d.). 1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial. Open forum infectious diseases. p. . [Online].